The Aβ42 Peptide and IAPP Physically Interact in a Yeast-Based Assay

Int J Mol Sci. 2023 Sep 15;24(18):14122. doi: 10.3390/ijms241814122.

Abstract

Numerous studies have demonstrated that people with type 2 diabetes mellitus (associated with IAPP peptide aggregation) show an increased incidence of Alzheimer's disease (associated with Aβ aggregation), but the mechanism responsible for this correlation is presently unknown. Here, we applied a yeast-based model to study the interactions of IAPP with PrP (associated with TSEs) and with the Aβ42 peptide. We demonstrated that fluorescently tagged IAPP forms detergent-resistant aggregates in yeast cells. Using the FRET approach, we showed that IAPP and Aβ aggregates co-localize and physically interact in yeast cells. We also showed that this interaction is specific and that there is no interaction between IAPP and PrP in the yeast system. Our data confirmed a direct physical interaction between IAPP and Aβ42 aggregates in a living cell. Based on these findings, we hypothesize that this interaction may play a crucial role in seeding Aβ42 aggregation in T2DM patients, thereby promoting the development of AD.

Keywords: Alzheimer’s disease; FRET; IAPP; PrP; amyloid beta; amyloidosis; protein aggregation; protein–protein interactions; type 2 diabetes mellitus.

MeSH terms

  • Alzheimer Disease*
  • Amyloid beta-Peptides
  • Diabetes Mellitus, Type 2*
  • Humans
  • Islet Amyloid Polypeptide
  • Saccharomyces cerevisiae

Substances

  • Amyloid beta-Peptides
  • amyloid beta-protein (1-42)
  • Islet Amyloid Polypeptide